Sleep disorders in Parkinson's disease

Clinical Cornerstone

Volumn 6, Issue 1 SUPPL. 1, 2004, Pages

  Thorpy, Michael J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; HYPNOTIC AGENT; IMIPRAMINE; LEVODOPA; LONG ACTING DRUG; MELATONIN; MIRTAZAPINE; MODAFINIL; QUETIAPINE; ROPINIROLE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZALEPLON; ZOLPIDEM;

ACTIMETRY; AGITATION; ANAMNESIS; ANTICHOLINERGIC EFFECT; ANXIETY; BEHAVIOR THERAPY; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DELIRIUM; DEMENTIA; DEPRESSION; DROWSINESS; DYSKINESIA; FALLING; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INSOMNIA; MEDICAL DOCUMENTATION; MICTURITION DISORDER; MOTOR DYSFUNCTION; NARCOLEPSY; NERVOUS SYSTEM FUNCTION; NIGHT SLEEP; NIGHTMARE; PANIC; PARASOMNIA; PARKINSON DISEASE; POLYSOMNOGRAPHY; PREVALENCE; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WALKING; SOMNOLENCE; SYNCOPE; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 2942726024     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)90013-0     Document Type: Article

References (56)

1. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry. 2003;54: 363-375.
2. Chokroverty S. Sleep and degenerative neurologic disorders. Neurol Clin. 1996;14:807-826.
3. Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson's disease and sleep. Sleep Med Rev. 2003;7:115-129.
4. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease: A self-reported, community-based survey. Sleep Med. 2002;3:147-149.
5. Scaravilli T, Gasparoli E, Rinaldi F, et al. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci. 2003;24:209-210.
6. Shochat T, Loredo J, Ancoli-Israel S. Sleep disorders in the elderly. Curr Treat Options Neurol. 2001;3: 19-36.
7. Autret A, Lucas B, Mondon K, et al. Sleep and brain lesions: A critical review of the literature and additional new cases. Neurophysiol Clin. 2001;31:356-375.
8. Lai YY, Siegel JM. Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder. Mol Neurobiol. 2003;27:137-152.
9. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: Epidemiology and management. CNS Drugs. 2001;15:267-275.
10. Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58:341-346.
11. Cantor CR, Stern MB. Dopamine agonists and sleep in Parkinson's disease. Neurology. 2002;58(Suppl 1): S71-S78.
12. Trenkwalder C. Sleep dysfunction in Parkinson's disease. Clin Neurosci. 1998;5:107-114.
13. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord. 2002;17:775-781.
14. Rye DB. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol. 2003; 5:231-239.
15. Hess CW. Sleep disorders and dementia [in German]. Schweiz Rundsch Med Prax. 1997;86:1343-1349.
16. Ganguli M, Reynolds CF, Gilby JE. Prevalence and persistence of sleep complaints in a rural older community sample: The MoVIES project. J Am Geriatr Soc. 1996;44:778-784.
17. Avidan AY. Insomnia in the geriatric patient. Clin Cornerstone. 2003;5(3):51-60.
18. Schafer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol. 2000;247(Suppl 4): IV24-IV27.
19. Pollak P, Tranchant C. Other symptoms of advanced stage Parkinson's disease [in French]. Rev Neurol (Paris). 2000;156(Suppl 2):165-173.
20. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson's disease: What is currently known? CNS Drugs. 2003;17:593-600.
21. Caap-Ahlgren M, Dehlin O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr. 2001;32:23-33.
22. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: A prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000;69:584-589.
23. Valldeoriola F, Molinuevo J. Therapy of behavioral disorders in Parkinson's disease. Biomed Pharmacother. 1999;53:149-153.
24. Merino-Andreu M, Arnulf I, Konofal E, et al. Unawareness of naps in Parkinson's disease and in disorders with excessive daytime sleepiness. Neurology. 2003;60:1553-1554.
25. Comella C. Sleep episodes in Parkinson's disease: More questions remain. Sleep Med. 2003;4:267-268.
26. Brodsky MA, Godbold J, Roth T, Olano CW. Sleepiness in Parkinson's disease: A controlled study. Mov Disord. 2003;18:668-672.
27. Kumar S, Bhatia M, Behari M. Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS). Sleep Med. 2003; 4:339-342.
28. Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med. 2003;4:275-280.
29. Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C, et al. Restless legs syndrome. J Neurol Neurosurg Psychiatry. 2001;71:143-146.
30. Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology. 2002;59:585-589.
31. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998;51:526-529.
32. Iranzo A. The importance of sleep medicine consultation for diagnosis of REM sleep behavior disorder in most patients with Parkinson's disease. Sleep Med. 2002;3:537-538.
33. Neven AK, Middelkoop HA, Kemp B, et al. The prevalence of clinically significant sleep apnoea syndrome in The Netherlands. Thorax. 1998;53:638-642.
34. Arnulf I, Derenne JP. Respiratory disorders during sleep in degenerative diseases of the brain stem [in French]. Rev Neurol (Paris). 2001;157:S148-S151.
35. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
36. Ancoli-Israel S, Clopton P, Klauber MR, et al. Use of wrist activity for monitoring sleep/wake in demented nursing-home patients. Sleep. 1997;20:24-27.
37. Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clin Cornerstone. 2003;5(3):28-40.
38. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10:45-56.
39. Bootzin RR. Stimulus control treatment for insomnia. In: Proceedings of the 80th Annual Convention of the American Psychological Association. Washington, DC: American Psychological Association; 1972:395-396.
40. Kleitman N. Sleep and Wakefulness as Alternating Phases in the Cycle of Existence. Chicago, Ill: University of Chicago Press; 1939.
41. Engle-Friedman M, Bootzin RR, Hazelwood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol. 1992;48:77-90.
42. Chung TH, Deane KH, Ghazi-Noori S, et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord. 2003; 10:59-65.
43. Geroldi C, Frisoni GB, Bianchetti A, Trabucchi M. Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord. 1997;8:188-197.
44. Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8:109-121.
45. Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: A double-blind, placebo-controlled, crossover trial. Am J Med. 1997; 102:60-66.
46. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology. 2002; 59:1573-1579.
47. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: A post-marketing surveillance of 16,944 cases. Int Clin Psychopharmacol. 1998;13:157-167.
48. Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson's disease. Lancet. 1997;349:1222-1223.
49. Lavoisy J, Marsac J. Zolpidem in Parkinson's disease. Lancet. 1997;350:74.
50. Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc. 2001;49:1685-1690.
51. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: Safety considerations. Drug Saf. 2003;26:643-659.
52. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med. 2003;4: 281-284.
53. Hogl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology. 2003;28:1866-1870.
54. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75:92-97.
55. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25: 905-909.
56. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24:87-90.